Immuneering Corp (IMRX)
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immuneering Corporation
- atebimetinibREADOUTCash runway at this date: 16mo
- atebimetinibREADOUTCash runway at this date: 10mo
- atebimetinibREADOUTCash runway at this date: 4mo
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib, GnP
Pancreatic Cancer, Pancreatic Cancer Metastatic +6
NCT07562152Enrollment510StartJun 2026Primary CompletionJun 2028est.READOUT • p=0.000CompletionFeb 2029est. - Phase 1/2Active, not recruiting
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
Advanced Solid Tumor, Pancreatic Adenocarcinoma +2
NCT05585320Enrollment209StartOct 2022Primary CompletionJun 2027est.CompletionJun 2028est. - Phase 1/2Completed
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
IMM-6-415
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma +2
NCT06208124Enrollment30StartFeb 2024Primary CompletionApr 2025CompletionApr 2025
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Recruiting | Atebimetinib, GnP | NCT07562152 |
| Phase 1/2 | Active, not recruiting | IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) | NCT05585320 |
| Phase 1/2 | Completed | IMM-6-415 | NCT06208124 |